delavirdine
Sign in to saveDelavirdine (DLV) (brand name Rescriptor) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that was marketed by ViiV Healthcare. It was used as part of highly active antiretroviral therapy (HAART) for the treatment of HIV-1 in the late 1990s and early 2000s. It is presented as the mesylate. The recommended dosage is 400 mg (as four 100-mg tablets or two 200-mg tablets) three times a day.
Article
4 sectionsContents
- Interactions
- Adverse effects
- Synthesis
- References
{{Drugbox | verifiedrevid = 460774806 | image = Delavirdine.svg | image_class = skin-invert-image | image2 = Delavirdine ball-and-stick model.png | image_class2 = bg-transparent | width = 250
| tradename = Rescriptor | Drugs.com = | MedlinePlus = a600034 | pregnancy_AU = B3 | routes_of_administration = By mouth | ATC_prefix = J05 | ATC_suffix = AG02 | ATC_supplemental =